Company intelligence / Profile preview

DS Biopharma

Dublin, Leinster, Irelanddsbiopharma.com ↗
Ownership
Private
Employees
~6
Development stage
Phase 2
01

Overview

Positive results from a study where continued treatment with 5% DS107 cream showed efficacy; two abstracts accepted at the Atopic Dermatitis Centre of Reference and Excellence (ADCARE) 2021 conference

Therapeutic areas
GastroenterologyPulmonologyMetabolic DisordersEndocrinologyDermatology
Modalities
Bioactive lipids
Industry
Biotech
02

Drug pipeline

4 assets

DS107E

2

3 more assets in the full pipeline.

Request access →
03

Partnerships

Nuvothera (option to license rights to develop and commercialize EPADILIN in the US)

Beyond the preview

Go deeper on DS Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DS Biopharma.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call